'First-In-Man' directed pre-clinical development of an anti-cancer agent - CYC065

点击翻译按钮获取中文摘要

Cyclacel has developed a novel clinical candidate NCE affecting previously unexplored pathways for treatment of acute leukaemia. The compound has a strong rationale for use as a stratified medicine for adult, infant and paediatric indications which have a high unmet medical need. The drug development project encompasses preclinical validation of marker assays for clinical stratification of patients, 'First-In-Man' (FIM)-directed preclinical development, clinical formulation and manufacture of the compound for Phase 1 testing, and testing of combinations with approved and investigational therapeutic agents to facilitate clinical development of the clinical candidate in the target diseases. Success will attract further investment in a UK and EU based development programme, securing additional jobs and will provide access to a new investigational medicine for both adult and infant patients with poor prognosis diseases.